Vertex Telaprevir Nearing Phase III With Final Installment Of PROVE Program
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Vertex expects to complete enrollment in PROVE 3, its Phase IIb trial of the protease inhibitor telaprevir (VX-950), by the end of the second quarter and initiate Phase III trials of the hepatitis C agent in the second half of the year, Executive VP-Medicines Development John Alam told analysts during a Feb. 1 year-end earnings call.